Legal & General Group
ARGS

Legal & General Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Legal & General Group’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-89
Closed -$1K – 3475
2017
Q1 		$1K Hold
89
– – ﹤0.01% 3265
2016
Q4 		$9K Buy
+89
New +$8.33K ﹤0.01% 3242

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Legal & General Group's ARGS Position: Q2 2017 in Review

Legal & General Group sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 89 shares — an estimated $1K sold.

Legal & General Group first reported a position in ARGS in Q4 2016 and held it in 2 quarters. The position peaked at $9K in Q4 2016. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • Legal & General Group reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Legal & General Group sold 89 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $1K.
  • Legal & General Group first reported a position in Argos Therapeutics, Inc. in Q4 2016 and held it in 2 quarters.
  • Legal & General Group's Argos Therapeutics, Inc. position peaked at $9K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Legal & General Group's 13F filing for Q2 2017, filed 3 Aug 2017.